SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI

SGLT2 inhibitors can reduce the incidence of abnormal blood glucose caused by statins in non-diabetes patients with HFrEF after PCI

Abstract Background Taking statins for a long time is associated with an increased risk of new-onset diabetes mellitus. Sodium-glucose cotransporter-2 (SGLT2) inhibitors can reduce insulin resistance and improve pancreatic β-cell function. Methods and results In total, 333 non-diabetes patients with...

Full description

Bibliographic Details
Main Authors: Yulin Yang, Xiaolin Wang, Yongchao Wang, Hao Xu, Jian Li
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Cardiovascular Disorders
Subjects:
Abnormal blood glucose
SGLT2 inhibitors
Heart failure
Statins
Online Access:https://doi.org/10.1186/s12872-023-03353-1

Internet

https://doi.org/10.1186/s12872-023-03353-1

Similar Items